Could a chemo booster tame a tough lymphoma?
NCT ID NCT07348575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding decitabine to standard chemotherapy (R-CHOP) helps people with a specific, aggressive lymphoma tied to the Epstein-Barr virus. About 80 newly diagnosed patients will be randomly assigned to get either the new combo or standard treatment alone. Researchers will track how long participants live without their cancer getting worse over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- decitabine combined with R-CHOP (a chemotherapy regimen)
- What this could lead to
- If successful, this could improve long-term control of EBV+ diffuse large B-cell lymphoma, potentially increasing the chance of staying cancer-free for two years.
- What could go wrong
- This is a mid-stage trial with only 80 participants, so results may not apply to all patients. Adding decitabine could also increase side effects like low blood counts or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV+ DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.